179 related articles for article (PubMed ID: 26816500)
1. Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series.
Delishaj D; Laliscia C; Manfredi B; Ursino S; Pasqualetti F; Lombardo E; Perrone F; Morganti R; Paiar F; Fabrini MG
J Contemp Brachytherapy; 2015 Dec; 7(6):437-44. PubMed ID: 26816500
[TBL] [Abstract][Full Text] [Related]
2. Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy.
Laliscia C; Coccia N; Fuentes T; Perrone F; Paiar F
J Contemp Brachytherapy; 2021 Dec; 13(6):615-619. PubMed ID: 35079246
[TBL] [Abstract][Full Text] [Related]
3. Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes.
Tormo A; Celada F; Rodriguez S; Botella R; Ballesta A; Kasper M; Ouhib Z; Santos M; Perez-Calatayud J
J Contemp Brachytherapy; 2014 Jun; 6(2):167-72. PubMed ID: 25097557
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate brachytherapy for non-melanoma skin cancer using tailored custom moulds - a single-centre experience.
Laliscia C; Fuentes T; Coccia N; Mattioni R; Perrone F; Paiar F
Contemp Oncol (Pozn); 2021; 25(1):12-16. PubMed ID: 33911976
[TBL] [Abstract][Full Text] [Related]
5. High-dose-rate brachytherapy in the treatment of skin Kaposi sarcoma.
Ruiz MÁG; Rivero JQ; García JLM; Rodríguez JJC; Kavadoy YR; Carmona MFR; Campos AC; Urra FG; Muñoz MCC; Herrero AR; Manzano PA
J Contemp Brachytherapy; 2017 Dec; 9(6):561-565. PubMed ID: 29441101
[TBL] [Abstract][Full Text] [Related]
6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
7. High-dose-rate skin brachytherapy with interstitial, surface, or a combination of interstitial and surface mold technique.
Brovchuk S; Park SJ; Shepil Z; Romanenko S; Vaskevych O
J Contemp Brachytherapy; 2022 Apr; 14(2):107-114. PubMed ID: 35494184
[TBL] [Abstract][Full Text] [Related]
8. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer.
Paravati AJ; Hawkins PG; Martin AN; Mansy G; Rahn DA; Advani SJ; Hoisak J; Dragojevic I; Martin PJ; Miller CJ; Sanghvi P
Pract Radiat Oncol; 2015; 5(6):e659-64. PubMed ID: 26432680
[TBL] [Abstract][Full Text] [Related]
9. Custom mold applicator high-dose-rate brachytherapy for nonmelanoma skin cancer-An analysis of 273 lesions.
Olek D; El-Ghamry MN; Deb N; Thawani N; Shaver C; Mutyala S
Brachytherapy; 2018; 17(3):601-608. PubMed ID: 29398593
[TBL] [Abstract][Full Text] [Related]
10. HDR brachytherapy for superficial non-melanoma skin cancers.
Gauden R; Pracy M; Avery AM; Hodgetts I; Gauden S
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):212-7. PubMed ID: 23551783
[TBL] [Abstract][Full Text] [Related]
11. Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature.
Delishaj D; Rembielak A; Manfredi B; Ursino S; Pasqualetti F; Laliscia C; Orlandi F; Morganti R; Fabrini MG; Paiar F
J Contemp Brachytherapy; 2016 Dec; 8(6):533-540. PubMed ID: 28115960
[TBL] [Abstract][Full Text] [Related]
12. The initial experience of electronic brachytherapy for the treatment of non-melanoma skin cancer.
Bhatnagar A; Loper A
Radiat Oncol; 2010 Sep; 5():87. PubMed ID: 20875139
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment.
Arenas M; Arguís M; Díez-Presa L; Henríquez I; Murcia-Mejía M; Gascón M; Gómez D; Lafuerza A; Mur E; Azón A; Rovirosa À; Sabater S
Brachytherapy; 2015; 14(6):859-65. PubMed ID: 26489922
[TBL] [Abstract][Full Text] [Related]
14. Tumor control and cosmetic outcome of weekly iridium-192 high-dose-rate brachytherapy for nonmelanoma skin cancers in the elderly.
Roberson J; Patel R; Slutsky JB; Ryu S; Xu Z; Valentine E
Brachytherapy; 2021; 20(4):818-827. PubMed ID: 33789824
[TBL] [Abstract][Full Text] [Related]
15. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
16. Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma.
Vavassori A; Riva G; Durante S; Fodor C; Comi S; Cambria R; Cattani F; Spadola G; Orecchia R; Jereczek-Fossa BA
J Contemp Brachytherapy; 2019 Oct; 11(5):443-448. PubMed ID: 31749853
[TBL] [Abstract][Full Text] [Related]
17. High-Dose-Rate Brachytherapy for the Treatment of Basal and Squamous Cell Carcinomas on Sensitive Areas of the Face: A Report of Clinical Outcomes and Acute and Subacute Toxicities.
Taylor JM; Dasgeb B; Liem S; Ali A; Harrison A; Finkelstein M; Cha J; Anne R; Greenbaum S; Sherwin W; Shi W
Adv Radiat Oncol; 2021; 6(2):100616. PubMed ID: 33912732
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate brachytherapy in treatment of non-melanoma skin cancer of head and neck region: preliminary results of a prospective single institution study.
Kalaghchi B; Esmati E; Ghalehtaki R; Gomar M; Jaberi R; Gholami S; Babaloui S; Nabavi M; Sotoudeh S; Khanjani N; Kazemian A; Amouzegar-Hashemi F; Aghili M; Lashkari M
J Contemp Brachytherapy; 2018 Apr; 10(2):115-122. PubMed ID: 29789760
[TBL] [Abstract][Full Text] [Related]
19. Electronic brachytherapy for non-melanoma skin cancer in Asians: Experience from a Taiwan medical center.
Tang TY; Tang JY; Chu-Sung Hu S; Chiao-Li Ke K; Cheng ST
J Formos Med Assoc; 2022 Nov; 121(11):2317-2323. PubMed ID: 35570050
[TBL] [Abstract][Full Text] [Related]
20. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
